Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15997205 | 0.84 | PTGS2 (0.59) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL4642193 | 0.84 | HTR2A (0.58) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL7778609 | 0.82 | ALDH1A1 (0.66) | MAPTALDH1A1POLBPKMKMT2A | |
| SCHEMBL15987340 | 0.82 | HTR2A (0.56) | TDP1HTR2ABCL9CTNNB1MAPT | |
| SCHEMBL12858126 | 0.82 | BCL9 (0.60) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL2597257 | 0.81 | HTR2A (0.55) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL278663 | 0.80 | BCL9 (0.62) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL4644859 | 0.80 | BCL9 (0.58) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL12529909 | 0.80 | HTR2A (0.54) | HTR2ABCL9CTNNB1MAPTALDH1A1 | |
| SCHEMBL409598 | 0.80 | HTR2A (0.59) | HTR2ABCL9CTNNB1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011081205-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | 一般社団法人ファルマＩＰ (JP) | 2011-07-07 | — | — | WO | claimed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| CN-100497326-C | 1-piperazine-and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-06-10 | — | — | CN | claimed |
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| CN-1922161-A | 1-piperazine-and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | CN | claimed |
| US-20060293310-A1 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | claimed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| CN-101538254-B | 1-piperazine-and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-07-27 | — | — | CN | disclosed |
| WO-2011081205-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | 一般社団法人ファルマＩＰ (JP) | 2011-07-07 | — | — | WO | disclosed |
| US-7973042-B2 | Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2011-07-05 | — | — | US | disclosed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687503-B2 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| CN-101538254-A | 1-piperazine-and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2009-09-23 | — | — | CN | disclosed |
| US-7482346-B2 | Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| CN-1922161-A | 1-piperazine-and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | CN | disclosed |
| US-20070027141-A1 | DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-02-01 | — | — | US | disclosed |
| US-20060293310-A1 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | disclosed |
| EP-1701946-A2 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005070910-A2 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-AVENTIS (FR) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | FAAH, FAAH2, CNR1 | TDP1 2917/4885HTR2A 33/4885BCL9 4319/4885 |
| US-20060293310-A1 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | FAAH, FAAH2, APEH | TDP1 2003/4885HTR2A 73/4885BCL9 4319/4885 |
| US-20070027141-A1 | DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | TDP1 3862/4885HTR2A 316/4885BCL9 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.